Growth Factor News and Research

RSS

USPTO issues patent to Silence Therapeutics' siRNA technology

Silence Therapeutics plc announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office.

23 Feb 2011

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program, currently under evaluation for the treatment of cancer.

22 Feb 2011

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.

18 Feb 2011

Statin drug may help prevent blindness in diabetics

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes.

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

FAK enzyme plays a key role in preparing lung tissue for metastatic development

A Massachusetts General Hospital study has identified a new role for an important enzyme in preparing lung tissue for the development of metastases.

17 Feb 2011

Study sheds light on novel functions of certain PCSK enzymes

Recent studies conducted at the Institut de recherches cliniques de Montr-al on a group of PCSK enzymes could have a positive impact on health, from cholesterol to osteoporosis.

17 Feb 2011

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

17 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

Researchers identify cell of origin for sarcoma

Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma. In a study published today as the Featured Article in the journal Cancer Cell, they report that childhood and adult sarcomas are linked in their biology, mutations and the cells from which these tumors first start.

16 Feb 2011

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics today announced the establishment of an alliance with KineMed, to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.

15 Feb 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

Tiny gold particles can help doctors detect CTCs in blood of patients with head, neck cancer

Tiny gold particles can help doctors detect tumor cells circulating in the blood of patients with head and neck cancer, researchers at Emory and Georgia Tech have found.

14 Feb 2011

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Resistance to leptin, a protein that plays a key role in regulating metabolism and appetite, may help prevent the development of acute respiratory distress syndrome and acute lung injury in individuals with type II diabetes, according to a study conducted by researchers in Chicago.

13 Feb 2011

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

11 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

8 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

7 Feb 2011

MetaMorphix announces sale under Chapter 11

MetaMorphix, Inc., an animal biotechnology company, announced its intention to sell all, or substantially all, of its assets as part of its reorganization under a sale in Chapter 11 pursuant to section 363 of the Bankruptcy Code. The Company also announced that American MedTech Advisors has been retained to assist in the sale of the Company.

5 Feb 2011

Engineered cells take control of the cells and microenvironment following transplantation

In work that could jumpstart the promising field of cell therapy, in which cells are transplanted into the body to treat a variety of diseases and tissue defects, researchers at Brigham and Women's Hospital (BWH) have engineered cells that could solve one of the key challenges associated with the procedure: control of the cells and their microenvironment following transplantation.

4 Feb 2011

Growth Factor News and Research

USPTO issues patent to Silence Therapeutics' siRNA technology

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Statin drug may help prevent blindness in diabetics

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

FAK enzyme plays a key role in preparing lung tissue for metastatic development

Study sheds light on novel functions of certain PCSK enzymes

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Researchers identify cell of origin for sarcoma

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Tiny gold particles can help doctors detect CTCs in blood of patients with head, neck cancer

Study: Leptin resistance may help prevent ARDS, ALI development in patients with type II diabetes

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

MetaMorphix announces sale under Chapter 11

Engineered cells take control of the cells and microenvironment following transplantation

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News